MDxHealth Completes Acquisition of Exosome Diagnostics

The latest update is out from MDxHealth ( (MDXH) ).

On September 15, 2025, MDxHealth SA announced the completion of its acquisition of Exosome Diagnostics, Inc. from Bio-Techne Corporation, which includes the ExoDx Prostate test. The acquisition, initially agreed upon on August 5, 2025, involves a total consideration of $15 million, with $5 million paid in stock at closing and the remainder to be paid over the next four years. This strategic acquisition is expected to enhance MDxHealth’s market position in precision diagnostics and expand its offerings in the urologic cancer diagnostics sector.

The most recent analyst rating on (MDXH) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.

Spark’s Take on MDXH Stock

According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.

MDxHealth’s stock score is primarily influenced by strong technical momentum, which is offset by financial instability and poor valuation metrics. The company’s growth potential is evident, but financial health remains a concern.

To see Spark’s full report on MDXH stock, click here.

More about MDxHealth

Mdxhealth is a leading precision diagnostics company specializing in providing actionable molecular information to personalize patient diagnosis and treatment. The company’s tests utilize proprietary genomic, epigenetic, exosomal, and other molecular technologies to assist physicians in diagnosing and prognosing urologic cancers and other urologic diseases. Mdxhealth operates in the U.S. with headquarters in Irvine, California, and additional laboratory operations in Waltham, Massachusetts, and Plano, Texas, while its European headquarters are located in Herstal, Belgium.

Average Trading Volume: 114,662

Technical Sentiment Signal: Hold

Current Market Cap: $181.2M

See more data about MDXH stock on TipRanks’ Stock Analysis page.